Literature DB >> 17958982

Tolerability of anti-tuberculosis treatment and HIV serostatus.

F Lanternier1, C Dalban, L Perez, F Bricaire, D Costagliola, E Caumes.   

Abstract

SETTING: Tuberculosis (TB) is frequent in human immunodeficiency virus (HIV) infected patients, but its treatment is hampered by adverse events and paradoxical reactions.
OBJECTIVE: To examine the impact of HIV infection and other factors on the risk and spectrum of adverse events related to anti-tuberculosis treatment in a prospective cohort study conducted between January 2003 and August 2004.
RESULTS: Of 105 patients treated for TB, 30 were HIV-infected. The overall incidence of adverse events was 122.5 +/- 18.5 per 100 patient-years (py) and the incidence of severe adverse events was 45.2 +/- 11.3/100 py. Age >50 years (OR 2.2, 95%CI 1.01-4.8, P = 0.046) and HIV infection (OR 3.9, 95%CI 2.1-7.5, P < 0.001) were independently associated with a higher risk of adverse events. Hepatitis (30.5/100 py) and neuropathy (28.6/100 py) were the most frequent adverse events. Hepatitis C virus infection was associated with hepatitis (OR 4.2, 95%CI 1.2-15.0, P = 0.028) and neuropathy with HIV infection (OR 3.8, 95%CI 1.1-13.7, P = 0.040).
CONCLUSION: Adverse reactions to anti-tuberculosis drugs are frequent. HIV infection and age >50 years are factors associated with such reactions, while hepatitis C virus infection is a risk factor for hepatitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958982

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  3 in total

1.  Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study.

Authors:  Natalie Lorent; Osee Sebatunzi; Gloria Mukeshimana; Jef Van den Ende; Joannes Clerinx
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

2.  Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study.

Authors:  Evans L Sagwa; Aukje K Mantel-Teeuwisse; Nunurai C Ruswa
Journal:  J Pharm Policy Pract       Date:  2014-10-21

3.  The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia.

Authors:  Evans Sagwa; Aukje Kaija Mantel-Teeuwisse; Nunurai Ruswa; Jean Paul Musasa; Shanthi Pal; Panganai Dhliwayo; Brian van Wyk
Journal:  South Med Rev       Date:  2012-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.